- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00339768
A Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong Province
Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong Province, China
The Division of Cancer Epidemiology and Genetics is conducting a collaborative randomized multi-intervention trial with the Beijing Institute for Cancer Research to evaluate the etiologic role of Helicobacter pylori, garlic, and certain micronutrients in the multi-step process of gastric carcinogenesis. The primary endpoint will not be cancer, but rather the precancerous lesions severe chronic atrophic gastritis, intestinal metaplasia, and dysplasia. The study is designed to detect a stabilizing or mild decrease in the expected age-related progression of precancerous lesions over the course of the trial. Thus the trial can be considered a study of the potential inhibitors of the process of gastric carcinogenesis. The trial will also provide an evaluation of therapy for H. pylori, including an assessment of reinfection rates, a critical need for formulating strategies for infection control in China and other developing countries. Participating in the trial are approximately 3400 adults aged 35-70 who were part of an ongoing survey of precancerous gastric lesions in 13 Linqu villages in Shandong Province. Linqu appears to be an ideal setting for the trial since stomach cancer rates are among the highes in the world, precancerous gastric lesions are prevalent, and the population is stable and well characterized. These individuals will be randomly assigned (taking H. pylori positivity into account) into 8 intervention groups according to a 2(3) factorial design. The interventions are: 1) initial treatment of H. pylori infection with ameprazole and amoxicillin followed by 2) daily supplementation with a combination of alpha-tocopherol, vitamin C, and selenium; and 3) daily supplementation with garlic extracts. No serious side effects have been seen from any of the interventions to date. The study staff will continue to monitor for possible adverse reactions and the population will receive routine medical care follow-up throughout the course of the trial.
As part of the ongoing study in Linqu, all participants received an endoscopic exam in the fall of 1994. Repeat gastroscopic exams with biopsies at 7 standard gastric sites will be conducted during March to May, 1999 and March to May, 2003 to detect early cancers and to evaluate gasatric mucosal status. The subjects will be categorized according to the most advanced lesions detected in all biopsies and assigned a severity score. The three major endpoints for analysis will be: 1) prevalence of dysplasia or cancer 2) prevalence of sever chronic atrophic gastritis, intestinal metaplasia, dysplasia, or cancer; and 3) average severity score.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Division of Cancer Epidemiology and Genetics is conducting an 8-year collaborative randomized multi-intervention trial with the Beijing Institute for Cancer Research to evaluate the etiologic role of Helicobacter pylori, garlic, and certain micronutrients in the multi-step process of gastric carcinogenesis. The primary endpoint will not be cancer, but rather the precancerous lesions severe chronic atrophic gastritis, intestinal metaplasia, and dysplasia. The study is designed to detect a stabilizing or mild decrease in the expected age-related progression of precancerous lesions over the course of the trial. Thus the trial can be considered a study of the potential inhibitors of the process of gastric carcinogenesis. The trial will also provide an evaluation of therapy for H. pylori, including an assessment of reinfection rates, a critical need for formulating strategies for infection control in China and other developing countries. Participating in the trial are approximately 3400 adults aged 35-70 who were part of an ongoing survey of precancerous gastric lesions in 13 Linqu villages in Shandong Province. Linqu appears to be an ideal setting for the trial since stomach cancer rates are among the highest in the world, precancerous gastric lesions are prevalent, and the population is stable and well characterized. These individuals will be randomly assigned (taking H. pylori positivity into account) into 8 intervention groups according to a 2(3) factorial design. The interventions are: 1) initial treatment of H. pylori infection with omeprazole and amoxicillin followed by 2) daily supplementation with a combination of alpha-tocopherol, vitamin C, and selenium; and 3) daily supplementation with garlic extracts. Compliance was excellent and no serious side effects were seen from any of the interventions.
As part of the ongoing study in Linqu, all participants received an endoscopic exam in the fall of 1994. Repeat gastroscopic exams with biopsies at 7 standard gastric sites conducted during March to May, 1999 and March to April, 2003 to detect early cancers and to evaluate gastric mucosal status. The subjects will be categorized according to the most advanced lesions detected in all biopsies and assigned a severity score. The three major endpoints for analysis will be: 1) prevalence of dysplasia or cancer 2) prevalence of severe chronic atrophic gastritis, intestinal metaplasia, dysplasia, or cancer; and 3) average severity score.
The major endpoint paper was published in JNCI in 2006. Additional analyses of the trial data are underway. A continuation study is proceeding that will allow for follow-up of the approximately 3070 remaining trial participants through 2010 on the long-term effects of the previous treatments on gastric cancer incidence and on cause-specific death rates and allow approximately 364 participants in the previous study with advanced gastric lesions in 2003 an opportunity for annual endoscopic screening for gastric cancer.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Beijing Institute for Cancer Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
Ages 35-670 in the 14 Linqu villages who received endoscopy examinations in the fall of 1994.
Both men and women will be included.
Patients must sign an informed consent form indicating a willingness to participate in the 42-month trial.
Must be free of debilitating chronic disease.
Must not report allergies to penicillin or similar medications.
Must not have had previous treatment for H. pylori.
Must not have a history of bleeding disorder.
Must not be taking vitamin/mineral supplements on a regular basis.
EXCLUSION CRITERIA:
Persons with cancer (except resected non-melanotic skin cancer), heart failure, emphysema, and other life-threatening illness will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Amox/omepr
2 weeks; placebo controlled
|
To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid.
This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
|
Experimental: Garlic
Supplement for 7 years; placebo controlled
|
To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid.
This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
|
Experimental: Vitamins
Supplement for 7 years; placebo controlled
|
To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid.
This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Precancerous gastric lesions
Time Frame: 7 years
|
prevention of cancer
|
7 years
|
Gastric cancer incidence
Time Frame: 15 years
|
prevention of caner
|
15 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Side effects
Time Frame: 7 years
|
7 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mitchell H Gail, M.D., National Cancer Institute (NCI)
Publications and helpful links
General Publications
- Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992 Dec 15;52(24):6735-40.
- You WC, Blot WJ, Chang YS, Ershow AG, Yang ZT, An Q, Henderson B, Xu GW, Fraumeni JF Jr, Wang TG. Diet and high risk of stomach cancer in Shandong, China. Cancer Res. 1988 Jun 15;48(12):3518-23.
- You WC, Blot WJ, Li JY, Chang YS, Jin ML, Kneller R, Zhang L, Han ZX, Zeng XR, Liu WD, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res. 1993 Mar 15;53(6):1317-21.
- Guo Y, Li ZX, Zhang JY, Ma JL, Zhang L, Zhang Y, Zhou T, Liu WD, Han ZX, Li WQ, Pan KF, You WC. Association Between Lifestyle Factors, Vitamin and Garlic Supplementation, and Gastric Cancer Outcomes: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6):e206628. doi: 10.1001/jamanetworkopen.2020.6628.
- Li WQ, Zhang JY, Ma JL, Li ZX, Zhang L, Zhang Y, Guo Y, Zhou T, Li JY, Shen L, Liu WD, Han ZX, Blot WJ, Gail MH, Pan KF, You WC. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ. 2019 Sep 11;366:l5016. doi: 10.1136/bmj.l5016.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 999995029
- OH95-C-N029
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Precancerous Gastric Lesions
-
Nantes University HospitalCompletedGastric Cancer | Gastric Precancerous LesionsFrance
-
Erzincan Military HospitalCompletedCervical Precancerous LesionsTurkey
-
University Hospital, BordeauxCompletedPrecancerous Lesions of the Oral MucosaFrance
-
Inovio PharmaceuticalsUniversity of PennsylvaniaCompletedAerodigestive Precancerous Lesions and MalignanciesUnited States
-
Azienda Socio Sanitaria Territoriale degli Spedali...RecruitingOral Premalignant LesionsItaly
-
Cairo UniversityCompletedOral Premalignant LesionsEgypt
-
Leiden UniversityDutch Cancer Society; ISA Pharmaceuticals; Top Institute PharmaCompleted
-
Xiyuan Hospital of China Academy of Chinese Medical...Guangdong Provincial Hospital of Traditional Chinese Medicine; Beijing Friendship... and other collaboratorsRecruiting
-
Taipei Medical UniversityUnknownSmoking | Precancerous Lesions | Cancer Cervix UterusTaiwan
-
Institut PasteurAssistance Publique - Hôpitaux de ParisRecruitingGastric Cancer | Gastric Precancerous Condition | Gastric LesionFrance
Clinical Trials on Amoxicillin/omeprazole
-
Infan Industria Quimica Farmaceutica NacionalHospital Universitário Oswaldo CruzUnknownGastritis | Helicobacter Pylori Infection
-
National Taiwan University HospitalNational Science Council, TaiwanCompletedHelicobacter Pylori Infection | Duodenal UlcerTaiwan
-
RedHill Biopharma LimitedCompletedDyspepsia | Helicobacter Pylori InfectionUnited States
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityRecruitingComparison of Efficacy of Triple Regimen Based on Clarithromycin VS Metronidazole in Children (CETR)H Pylori GastritisPakistan
-
Javeriana UniversityUniversidad Nacional de ColombiaCompletedTherapy | H.Pylori Infection | CYP2C19 Polymorphism
-
University of California, Los AngelesMichael J. Fox Foundation for Parkinson's ResearchTerminatedParkinson's Disease | Helicobacter Infections | Motor FluctuationsUnited States
-
Dow University of Health SciencesCompleted
-
Al-Azhar UniversityMinistry of Health, KuwaitCompletedHelicobacter Pylori Infection
-
Tabriz UniversityCompletedCentral Serous ChorioretinopathyIran, Islamic Republic of
-
Washington University School of MedicineCompletedDyspepsia | Helicobacter Pylori InfectionUnited States